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Abstract: Epilepsy is a common neurological disorder associated with increased morbidity and
mortality. Sudden unexpected death in epilepsy, also known as SUDEP, is the main cause of death in
patients with epilepsy. SUDEP has an incidence of 1.2 per 1000 person-years in adults and 0.2 per
1000 person-years in children. SUDEP accounts for 8–17% of deaths in patients with epilepsy. It is
commonly associated with a history of generalized tonic-clonic seizures, and its risk may be increased
by other factors such as postictal electroencephalographic suppression, prone sleeping position,
altered heart rate variability, conduction abnormalities, gender, or antiepileptic medications. Recently,
electrocardiograms, electroencephalograms, and imaging markers have helped clinicians stratify
SUDEP risk and identify patients in need of close monitoring. However, the pathophysiology of
SUDEP is likely multifactorial and still unknown. Improving the knowledge of SUDEP incidence,
risk factors, and biomarkers can help design and implement effective prevention strategies.
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1. Introduction
Epilepsy is a common neurological disorder of the central nervous system characterized by
recurrent seizures with or without convulsions [1]. Currently, seizures are classified into four groups:
simple (status epilepticus), partial (seizures in infants and young adults), complex (generalized
tonic-clonic seizures (GTCS)), and unclassified seizures. Those associated with an altered state
of consciousness, particularly GTCS and uncontrolled repetitive seizures or status epilepticus, are
associated with increased morbidity and mortality, especially in infants and young populations [2,3].
In general, patients with epilepsy are two- to three-times more likely to die early than the
general population [4]. Several possible causes of death have been reported in patients with epilepsy,
including seizure complications, status epilepticus, or even suicide, but the main current cause is
sudden unexpected death in epilepsy (SUDEP). Today, SUDEP is defined as a “sudden, unexpected,
witnessed or unwitnessed, non-traumatic, and non-drowning death in patients with epilepsy with or
without evidence for a seizure, and excluding documented status epilepticus, in which postmortem
examination does not reveal a structural or toxicological cause of death” [5].
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The concept of SUDEP was first defined in the 1990s based on whether an autopsy was performed
and competing factors were present [6,7]. A new classification by Nashef et al. in 2012 helped
refine SUDEP definitions and classification [5]. The authors introduced definite SUDEP plus and
probable SUDEP plus, which are classifications that consider cases in which the individual had other
concomitant conditions. The authors also defined near SUDEP, identifying resuscitated cases after a
cardiopulmonary arrest of unidentified origin with survival of >1 h (Table 1). Today, SUDEP is likely
underestimated; thus, improved criteria to classify the cause of death would allow more accurate
tracking of this condition. Devinsky et al. recently suggested additional clinical and pathological
criteria for more consistent and reliable classification of epilepsy-related mortality [8]. Lamberts
et al. [9] observed that 62% of SUDEP cases happened between midnight and noon, and that 58% of
SUDEP cases were sleep-related. Further, they found that individuals whose deaths were associated
with SUDEP were two-times more likely to have nocturnal seizures than those without SUDEP [9].
SUDEP occurs at night likely because of multiple factors, including both situational factors (absence of
caregivers) and physiological modifications (circadian rhythms) [10].
Table 1. Proposed sudden unexpected death in epilepsy (SUDEP) definition and classification [5].
Classification Definition
Definite sudden unexpected death
in epilepsy (SUDEP)
Sudden, unexpected, witnessed or unwitnessed, non-traumatic, and
non-drowning death that occurs in benign circumstances in an
individual with epilepsy, with or without evidence for a seizure, and
excludes documented status epilepticus, in which post-mortem
examination does not reveal a cause of death.
Definite SUDEP plus
Death satisfying criteria for definite SUDEP, if a concomitant condition
other than epilepsy is identified before or after death, if the death might
have been due to the combined effect of both conditions, and if autopsy
or direct observations or recording of the terminal event did not prove
the concomitant condition to be the cause of death.
Probable SUDEP or probable
SUDEP plus Same definition as definite SUDEP or SUDEP plus, but without autopsy.
Possible SUDEP A competing cause of death is present.
Near-SUDEP or near-SUDEP plus
A patient with epilepsy who survives resuscitation for more than an
hour after cardiorespiratory arrest and has no structural cause identified
after investigation.
Not SUDEP A clear alternative cause of death is identified.
Unclassified Incomplete information available; impossible to classify.
2. Epidemiology
The current incidence of SUDEP remains undetermined, mainly because SUDEP and epilepsy are
frequently underreported as possible or certain causes of death by clinicians and medical examiners [11].
This fact can be (partially) explained by two factors: the lack of accurate and proper knowledge
of SUDEP among many practitioners, and the presence of only unspecific—and inconstant—signs
in the autopsy (e.g., cortical dysplasia, hippocampal sclerosis, and eosinophilic neuronal change).
SUDEP incidence varies depending on the sample population, age range, type of epilepsy, classification
systems, diagnosis methods, and recorded cause of death [12–14]. Previous estimates indicate that
SUDEP risk in young adults (aged 20–45 years) with epilepsy is up to 27-times higher than in the
general population of the same age [15].
In 2017, the American Academy of Neurology (AAN) and American Epilepsy Society (AES)
published a guideline on SUDEP, reporting an incidence per 1000 epilepsy person-years of 0.22
(95% confidence interval (CI): 0.16–0.31) in children and 1.2 (95% CI: 0.64–2.32) in adults—concluding
that patients should be counseled that SUDEP risk is modest in children and small in adults [16].
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In 2018, a meta-analysis of 45 cohorts of SUDEP cases estimated that the SUDEP pooled incidence rate
was 0.0014 (95% CI: 0.0009–0.0022) events per person-year. In particular, three variables—prospective
design, mean patient age, and nature of the study population—explained 22% of the heterogeneity of
the incidence rate [17].
As indicated, SUDEP incidence is highest among young adults, while it is considerably lower
in the pediatric population. In individuals <14 years of age, SUDEP chiefly accounts for high-risk
cases, such as individuals with major neurological impairment or injury [13]. If the onset of epileptic
seizures occurs early and never fully remits, the risk of death is about 8% by 70 years of age. However,
this risk might vary substantially in different populations, depending on seizure type and extent of
seizure control [12]. In 2013, Holst et al. reported that the adjusted hazard ratio for death in young
patients with epilepsy was 5.4-times higher than in the general population, and the adjusted hazard
ratio for sudden death was 16.3-times higher than in the general population [15]. Consequently,
epilepsy is associated with a significantly higher risk of death and sudden death in adults and children.
Current AAN guidelines recommend that clinicians inform that SUDEP annually affects 0.2 per 1000
person-years in children with epilepsy and 1.2 per 1000 person-years in adults with epilepsy [16].
3. Risk Factors
The main cause of SUDEP remains unknown, and more than one mechanism seems to play a
role. Several risk factors specific for SUDEP have been identified in case-control studies on SUDEP
and non-SUDEP epilepsy deaths. Although identified risk factors vary due to the heterogeneity of
the studies and because models cannot accurately predict the seizure risk for individual patients,
some risk factors are recurrent. The strongest and most common risk factor for SUDEP is frequency of
seizures, particularly GTCS [13,18,19]. Patients with ≥3 GTCS per month have a 15-fold increased risk
of SUDEP. In addition, the presence of GTCS and not being seizure-free for 1–5 years are considered
risk factors [16] (Table 2).
Table 2. SUDEP risk factors.
Risk Factor
High Frequency of generalized tonic-clonic seizures (GTCS)
Moderate
Presence of GTCS
Not being seizure-free for 1–5 years
Not adding an antiepileptic drug when patients are medically refractory
Nocturnal supervision (risk reduction)
Use of nocturnal listening device (risk reduction)
Lack of proper/stable antiepileptic drug treatment and polytherapy have also been associated
with increased SUDEP risk [12,13,20]. Further, the presence of someone who can provide assistance at
night was reported to be protective in one case-control study [21]. Despite the lack of direct evidence,
preventive interventions targeting these risk factors could reduce the risk of SUDEP [13].
SUDEP occurs in all ages, although patients who are 20–40 years old have a higher risk of
SUDEP [22]. Both earlier age of onset and increased duration of epilepsy are risk factors for SUDEP [23].
SUDEP risk is doubtfully affected by ethnicity and gender, and it seems dependent on the population
studied. Despite identified risk factors, however, part of the diagnosed population does not experience
SUDEP, suggesting that other mechanisms are involved in the condition [14]. It is important to note
that young people’s risk of SUDEP is increased by intellectual disability, structural brain abnormalities,
and abnormal neurological assessment [3]. Besides neurological conditions, psychiatric comorbidities
also predispose to SUDEP [16].
A recent meta-analysis ranked the 10 leading risk factors derived from key cohort and population-
based studies (Table 3) [24].
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Table 3. Principal risk factors for SUDEP (adapted from Reference [24]).
Risk Factor Weighted Log Odds Ratio(Adjusted Log OR ÷ Standard Error (SE)) Reference
>3 GTCS per year (versus 0 seizures) 12.10 Hesdorffer et al. [25]
>13 Seizures of any type in the past year
(versus 0–2 seizures) 4.20 Nilsson et al. [26]
No AED * treatment (versus 1–2 AEDs) 3.78 Langan et al. [21]
3 AEDs (versus 1) 3.24 Nilsson et al. [26]
≥3 GTCS in past year (versus 0) 3.04 Walczak et al. [27]
11–20 GTCS in the past 3 months (versus 0–5) 2.39 Langan et al. [21]
Age at onset of 0–15 years (versus >45 years) 2.29 Nilsson et al. [26]
IQ <70 2.23 Walczak et al. [27]
3–5 changes in AEDs per year (versus 0) 2.16 Nilsson et al. [26]
>3 AEDs in the last visit (versus 0–2) 1.96 Walczak et al. [27]
* AED: antiepileptic drugs.
4. Sudden Unexpected Death in Epilepsy (SUDEP) Pathophysiology
Recent studies have extensively investigated the pathophysiology of SUDEP in different groups,
proposing four main mechanisms for SUDEP: cardiac dysfunction, respiratory dysfunction, brainstem
arousal system dysfunction, and dysregulation in the neurotransmitter and neuromodulator system [28].
Most results suggest a complex and multifactorial model. The MORTality in Epilepsy Monitoring
Unit Study (MORTEMUS) study focused on deaths occurring during video electroencephalogram
monitoring to ascertain the possible mechanisms of SUDEP on an international scale. The study results
suggest that the crucial mechanism leading to SUDEP starts with an early, centrally mediated, severe
alteration of both respiratory and cardiac functions after GTCS, which the authors consider as an early
postictal neurovegetative breakdown. Depending on the intensity, this mechanism might lead to instant
death or cardiorespiratory arrest after several minutes of altered cardiorespiratory function, most likely
intensified by profound hypoxia. It has been hypothesized that intrinsic mechanisms leading to or
associated with seizure termination are the origin of this centrally mediated neurovegetative breakdown
and postictal generalized electroencephalogram (EEG) suppression [23].
5. Genetics of SUDEP
Definite evidence has recently emerged concerning genetic susceptibility to SUDEP, suggesting
a highly polygenic contribution [18]. A gene associated with SUDEP should include a definite
pathogenic alteration that causes epilepsy, increasing SUDEP risk [12]. Numerous neurocardiac genes
have been identified as genomic biomarkers of disease severity and outcome, helping predict SUDEP
incidence [19]. Moreover, several pathogenic alterations in different genes have been reported to
increase SUDEP risk through different pathophysiological mechanisms. These genes encode proteins
related to epilepsy and the cardiorespiratory system [18,29]. Until now, few genes have been analyzed in
genetic testing (Table 4), but with next-generation sequencing and the low cost of these high-throughput
technologies, candidate genes can now be interrogated to explore new genetic causes.
Few studies have examined possible genetic risk factors in SUDEP. In these cases, the limiting
factor is sufficient DNA quality of samples collected during the life of the patient or extracted
from postmortem blood. However, there is increasing awareness of the importance of collecting
blood samples in unexplained sudden death to perform post-mortem genetic testing of main cardiac
arrhythmia genes [20]. Further, in 2017, Bagnall et al. performed exome sequencing from degraded
DNA derived from fixed postmortem tissues, which identified a de novo SCN1A frameshift variant
in a patient with SUDEP [20]. This study shows the possibility to analyze historical collections of
postmortem fixed tissues from SUDEP cases.
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Table 4. Genes associated with SUDEP (adapted from Reference [20]).
Gene Description Evidence for Association with SUDEP
SCN1A Sodium Voltage-Gated Channel Alpha Subunit 1 Animal model; de novo variants found inSUDEP cases
SCN2A Sodium Voltage-Gated Channel Alpha Subunit 2 De novo variants found in SUDEP cases
SCN5A Voltage-Gated Sodium Channel Subunit Alpha Nav1.5 De novo variant found in SUDEP case
SCN8A Sodium Voltage-Gated Channel Alpha Subunit 8 Animal model; de novo variants found inSUDEP cases
KCNA1 Potassium Voltage-Gated Channel Subfamily A Member 1 Animal model; variant found in SUDEP case
KCNQ1 Voltage-Gated Potassium Channel Subunit Kv7.1 Variants found in SUDEP cases
KCNH2 Voltage-Gated Potassium Channel Subunit Kv11.1 Variants found in SUDEP cases
DEPDC5 DEP Domain-Containing Protein 5 De novo variants found in SUDEP cases
5.1. Cardiac Arrhythmia Genes in SUDEP
Epilepsy can have damaging effects on cardiac function, which may play an important role in
the pathophysiology of SUDEP [30,31]. Epileptic seizures can induce malignant cardiac arrhythmias,
possibly due to seizure-related effects on the autonomic nervous system [20].
Mutations of ion channel genes have a major role in the pathogenesis of several epilepsies,
confirming that these are due to the impairment of ion channel function (channelopathies).
Voltage-gated channels play an essential role in neuronal excitability and it is not surprising that most
mutations associated with epilepsy have been identified in these genes [32].
In 2009, Aurlien et al. identified the first SCN5A mutation in a patient with idiopathic epilepsy,
suggesting that ion channel mutations are co-expressed in the brain and heart and predispose to both
epileptic seizures and cardiac arrhythmias [33]. In 2011, a larger retrospective analysis of autopsies
of SUDEP cases in a forensic center in Australia during a 16-year period identified 86 SUDEP cases.
The genetic analyses revealed six genetic mutations in voltage-gated ion channel genes KCNH2 and
SCN5A, as previously reported in long QT syndrome (LQTS) [34]. Sequencing of a family of four
hyperpolarization-activated cyclic nucleotide-gated cation channel genes (HCN1, HCN2, HCN3, and
HCN4) in the same cohort identified three non-synonymous variants (Phe738Cys and Pro802Ser in
HCN2, and Gly973Arg in HCN4).
The largest genetic study of SUDEP was done by Bagnall et al. in 2016 using exome sequencing-
based analysis of 61 SUDEP cases [35]. They analyzed cardiac arrhythmia, respiratory control,
and epilepsy genes, identifying four pathogenic and two candidate pathogenic variants of cardiac
arrhythmia genes: a de novo SCN5A Ile397Val variant, a Gly924Ala and Arg744* nonsense variant
in KCNH2, and a Tyr662* nonsense variant in KCNQ1. The variants in KCNQ1 and KCNH2 were
previously reported in patients diagnosed with LQTS, and these three variants were absent in more
than 60,000 population controls. The de novo variant in SCN5A is located in a highly conserved
transmembrane domain. All these variants are classified as likely pathogenic for LQTS. In addition,
the variants were found in one coronial SUDEP case and three SUDEP cases from the Melbourne
Epilepsy Research Centre cohort [20].
In 2016, our group performed next-generation sequencing on a cohort of 14 SUDEP cases using a
custom resequencing panel, including genes previously related to SUDEP as well as new candidate
genes. Four cases showed rare variants with complete segregation in SCN1A, FBN1, HCN1, SCN4A,
and EFHC1, and one case had a rare variant in KCNQ1 with incomplete penetrance. In four cases,
rare variants were detected in CACNA1A, SCN11A, SCN10A, and KCNQ1 genes, although no familial
segregation was performed due to a lack of DNA from relatives. This study confirmed the link between
epilepsy, sudden death, and cardiac disease, and further identified new potential candidate genes for
SUDEP: FBN1, HCN1, SCN4A, EFHC1, CACNA1A, SCN11A, and SCN10A [36].
The identification of all these gene variants previously associated with LQTS raises some questions
about whether the variants are responsible for both epilepsy and sudden death, or if patients with or
without gene variants have differing pathophysiology. Further, the identification of LQTS variants in
individuals with SUDEP would allow the identification of variants in family members with or without
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epilepsy who are at risk of arrhythmia. SUDEP is also associated with variants and mutations of
neurocardiac channelopathy genes [37]. This evidence could suggest some preventive measures to
prevent sudden death, including avoidance of medications that may prolong the QT interval, taking
antiarrhythmic drugs such as beta-blockers, and prophylactic interventions for possible lethal cardiac
arrhythmias, such as implantable cardioverter defibrillators [20].
5.2. Genetic Epilepsy Syndromes and SUDEP Risk
Some genetic epilepsy syndromes have a high risk of SUDEP, and the associated pathogenic
variants may be appropriate biomarkers [20]. Pathogenic alterations in SCN1A (associated with Dravet
syndrome, a genetic epileptic encephalopathy in which a SCN1A loss-of-function mutation is found in
80% of cases) or in SCN8A (associated with early-infantile encephalopathy) are examples of variants
co-expressed in both brain and heart that increase the risk of SUDEP [38]. However, it remains to be
determined why these epilepsies caused by genetic variants should have a high risk of SUDEP.
A study by our group that included 20 epilepsy patients with personal or family history of heart
rhythm disturbance/cardiac arrhythmia/sudden death identified four missense variants in epilepsy
genes CDKL5, CNTNAP2, GRIN2A, and ADGRV1, with complete segregation within the family [39].
In 2016, Bagnall et al. [35] performed an exome-based analysis of cardiac arrhythmia, respiratory
control, and epilepsy genes in SUDEP. They analyzed 61 SUDEP cases and found one previously
described pathogenic mutation and five candidate pathogenic variants in DEPDC5. They also identified
a variant in sodium channel gene SCN1A, related to genetic epilepsy plus febrile seizures and a rare
cause of Brugada syndrome, and SCN2A, associated with epileptic encephalopathies [35].
5.3. Respiratory Genes and SUDEP Risk
The association between neuronal regulation of respiratory function and SUDEP came from
functional in vivo models. DBA/1 and DBA/2 (Dilute Brown Non-Agouti) mice are useful animal
models to study SUDEP because these mice exhibit generalized convulsive seizures followed by
respiratory arrest [40]. Respiratory arrest can be prevented by treatments that activate serotonin
(5-HT) receptors, as subtypes of 5-HT help regulate normal respiration [41]. Further, congenital heart
hypoventilation syndrome is a disorder characterized by increased frequency of bradyarrhythmia
and is mainly caused by expansion of an alanine repeat in PHOX2B. This gene could be a good target
for SUDEP, although no studied SUDEP cases carry a variant in this gene [42]. Moreover, no genetic
variants in respiratory control genes (ASCL1, BDNF, EDN3, GDNF, and RET) were identified in exome
analysis of 61 SUDEP cases [35].
5.4. Future Directions
Although considerable progress has been made in SUDEP in recent years, there is much work to be
done on the genetic diagnosis of this condition. Several genes responsible for inherited channelopathies
are linked to SUDEP, and several recently identified potential candidate genes with positive segregation
indicate that a common cardiac neuron gene expression may underlie the basis of sudden death in
epilepsy. Although in silico tools are being used to predict the possible pathogenicity and could
help classify some variants, it is not recommended that these predictions be used as the sole source
of evidence to make a clinical assertion. Moreover, larger cohorts as well as in vivo and in vitro
studies will be required to ascertain the pathogenicity of these variants. Molecular genetic screening
also needs to become an inherent part of the post-mortem examination in cases labeled as SUDEP.
This genetic testing will enhance the ability to screen SUDEP victims’ family members, who may be
at-risk carriers of fatal cardiac disorders. Genetic interpretation requires multidisciplinary groups,
including geneticists working together with clinicians, forensic pathologists, and genetic counselors.
To best manage families, close interdisciplinary collaboration is essential.
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6. New Biomarkers
Although all individuals with epilepsy are at risk of SUDEP, the risk is not uniform across
patient groups. Biomarkers are needed to identify the individual risk of SUDEP and thus personalize
preventive interventions. Biomarkers might address innate risk factors of SUDEP, such as the genetic
profile, as well as acquired risk factors (some of which might change over time), such as the level of
post-GTCS brainstem dysfunction [43]. Three main tools are currently used: electrocardiogram (ECG),
electroencephalogram (EEG), and imaging biomarkers (MRI and fMRI).
In 2013, Scorza et al. [44] first mentioned the term microRNA in SUDEP; microRNAs (miRNAs)
are noncoding RNA molecules that play a critical role in gene expression regulation. These molecules
are involved in important biological processes, are potential biomarkers for cardiovascular disorders,
and can be detected in serum or plasma in a remarkably stable form. The authors suggested that
expression pattern modifications of circulating miRNAs may be related to abnormal underlying
cardiovascular processes, and could be identified and used as biomarkers for SUDEP [44]. In 2017,
De Matteis et al. [45] presented a case of SUDEP in comparison with 10 autopsies of traumatic
or asphyxia deaths. The authors analyzed expression profiles of several miRNAs (miR-301a-3p,
miR-194-5p, miR-30b-5p, mIR-342-5p, and miR-4446-3p) from the plasma and temporal lobe, and
identified a significant up-regulation of miR-301a-3p in the plasma (2.3-fold) and hippocampus (3.2-fold)
of the SUDEP case compared with controls [45]. However, this potential biomarker still needs to be
confirmed by additional cases.
7. Prevention of SUDEP
The main purpose of unravelling the incidence, risk factors, and biomarkers of SUDEP is to design
and implement effective prevention strategies. Education is the first measure of prevention—treating
physicians, primary care physicians, and neurologists must inform patients about risk factors for
morbidity and mortality associated with medically refractory epilepsy, and about the importance of
adhering to therapy and avoiding risky and/or unhealthy behaviors (e.g., sleeping in prone position,
insufficient sleep, excessive drinking) [30]. Reported preventive measures include effective seizure
control, nocturnal supervision, seizure monitoring, devices to protect the airway (e.g., anti-suffocation
pillows), selective serotonin reuptake inhibitors, and other medications (caffeine and other adenosine
antagonists have been proposed as hypothetical treatments) [28].
However, the evidence supporting these interventions is not robust [46,47]. The most effective
prevention of SUDEP is likely complete remission of GTCS [48]. Usually, SUDEP occurs during sleep
without supervision. Therefore, a preventive measure could involve using seizure and apnea detection
devices to recognize the initial step of SUDEP and thus start resuscitation procedures as soon as
possible. Cardiorespiratory resuscitation strategies have also been proposed as preventive measures
for SUDEP. In 2008, Strzelczyk et al. described that implantation of pacemakers and defibrillators
prevented ictal asystole in temporal lobe epilepsy patients [49].
8. Conclusions
SUDEP is the main cause of epilepsy-related premature mortality, especially in younger
populations. Different types of epilepsy populations complicate the identification of SUDEP cases
and, consequently, of its current incidence. Therefore, systematic methods to improve identification
and better understand the causes of this condition are needed. Advancing our knowledge of SUDEP
pathophysiologic mechanisms is the first step to reduce its incidence and elaborate new preventive
strategies. At the same time, diffusion of knowledge about SUDEP must be supported and amplified
inside scientific and medical communities to improve the quantity and quality of data available for
research. In addition, biomarkers such as ECG, EEG, and imaging markers will help clinicians further
stratify SUDEP risk and identify patients who need close monitoring. The identification of additional
risk factors and biomarkers will help develop new preventive interventions for patients and their
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families. Ultimately, education of both families and clinicians as well as basic and clinical research and
development of new treatments are needed to reduce the risk of SUDEP.
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